Classification of antituberculosis drugs: A new proposal based on the most recent evidence

European Respiratory Journal

Volumn 46, Issue 4, 2015, Pages 887-893

  Caminero, Jose A ^a,b   Scardigli, Anna ^b  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CARBAPENEM DERIVATIVE; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; THIOACETAZONE; THIONAMIDE; TUBERCULOSTATIC AGENT; CLAVULANIC ACID; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ADVERSE OUTCOME; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; TUBERCULOSIS; CLASSIFICATION; COMBINATION DRUG THERAPY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; INFECTIOUS DISEASE MEDICINE; PRACTICE GUIDELINE; PROCEDURES; STANDARDS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; CARBAPENEMS; CLAVULANIC ACID; CLOFAZIMINE; DIARYLQUINOLINES; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; INFECTIOUS DISEASE MEDICINE; LINEZOLID; NITROIMIDAZOLES; OXAZOLES; PRACTICE GUIDELINES AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84943258775     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00432-2015     Document Type: Conference Paper

References (61)

1. World Health Organization. Global tuberculosis report 2014. WHO/HTM/TB2014.08. Geneva, World Health Organization, 2014.
2. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
3. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013; 42: 156-168.
4. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
5. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
6. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.
7. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
8. D'Ambrosio L, Dara M, Tadolini M, et al. TB Elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
9. Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1.
10. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
11. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
12. World Health Organization. Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210 (Rev.1). Geneva, World Health Organization, 1996.
13. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva, World Health Organization, 2006.
14. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, World Health Organization, 2008.
15. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, World Health Organization, 2014.
16. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
17. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
18. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
19. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
20. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
21. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: Suppl. 2, S231-S279.
22. Caminero JA, ed. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. Paris, International Union Against Tuberculosis and Lung Disease, 2013.
23. Caminero JA, Matteelli A, Lange C. Treatment of TB. In: Lange C, Migliori GB, eds. Tuberculosis (ERS Monograph). Sheffield, European Respiratory Society, 2012; pp. 154-166.
24. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
25. Scardigli A, Caminero JA. Management of drug-resistant tuberculosis. Curr Respir Care Rep 2013; 2: 208-217.
26. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.
27. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009; 4: e6914.
28. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
29. Chang KC, Yew WW, Tam CM, et al. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review and cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57: 4097-4104.
30. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
31. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015; 45: 161-70.
32. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
33. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2011; 38: 730-733.
34. De Lorenzo S, Centis R, D'Ambrosio L, et al. On linezolid efficacy and tolerability. Eur Respir J 2012; 39: 770-772.
35. Sotgiu G, Centis R, D'Ambrosio L, et al. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290.
36. Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 2015; 45: 25-29.
37. Sotgiu G, Centis R, D'Ambrosio L, et al. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur Respir J 2015; 45: 287-289.
38. Stop TB Partnership. Global Drug Facility Product Catalogue. Geneva, World Health Organization, 2014.
39. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.
40. Koh WJ, Shim TS. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 1119-1120.
41. Chang KC, Yew WW, Cheung SW, et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother 2013; 57: 3445-3449.
42. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013; 42: 1449-1453.
43. Esposito S, Codecasa LR, Centis R. The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. Eur Respir J 2015; 45: 571-574.
44. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009; 53: 1290-1292.
45. Ibrahim M, Truffot-Pernot C, Andries, K, et al. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009; 180: 553-557.
46. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2013; 57: 2199-2203.
47. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
48. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
49. van Halsema C, Humphreys S, Bonington A. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 2014; 43: 292-294.
50. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2013.6. Geneva, World Health Organization, 2013.
51. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-2981.
52. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949-954.
53. Munang ML, O'Shea MK, Dedicoat M. Novel drugs and drug combinations for treating tuberculosis. BMJ 2014; 349: g5948.
54. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
55. Wells CD, Gupta R, Hittel N, et al. Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid. Eur Respir J 2015; 45: 1498-1501.
56. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB2014.23. Geneva, World Health Organization, 2014.
57. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
58. Payen MC, De Wit S, Martin C, et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 558-560.
59. England K, Boshoff HI, Arora K, et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2012; 56: 3384-3387.
60. Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
61. Dooley KE, Obuku EA, Durakovic N, et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013; 207: 1352-1358.